Stock Track | MannKind Shares Plunge Despite Q3 Beat as Afrezza Concerns Linger

Stock Track

Nov 08, 2024

Shares of MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company focused on inhaled therapeutic products, took a nosedive on November 8, 2024, plummeting by 5.95% in pre-market trading. This sharp decline came despite the company reporting better-than-expected earnings for the third quarter of 2024 the previous day.

While MannKind's Q3 2024 adjusted earnings per share of $0.05 surpassed analysts' estimates of $0.03, the company's revenue performance fell significantly short of expectations. MannKind reported revenue of $19.73 million, a staggering 61.5% lower than the year-ago quarter, missing analysts' projections of $74.50 million.

The primary concern for investors appears to be the underwhelming performance of MannKind's flagship product, Afrezza, an inhaled insulin product for diabetic patients. Afrezza's net revenue grew by a modest 12% year-over-year in Q3 2024, primarily driven by higher demand and improved gross-to-net adjustments. However, the company acknowledged facing headwinds throughout the year, including payers implementing double step edits and a shift in inventory at a major pharmacy chain and one of its specialty pharmacies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1177751945"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177751945\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177751945?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 22:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177751945","market":"hk","top_or_hot":-1,"title":"Stock Track | MannKind Shares Plunge Despite Q3 Beat as Afrezza Concerns Linger","media":"Stock Track","content":"<p>Shares of MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company focused on inhaled therapeutic products, took a nosedive on November 8, 2024, plummeting by 5.95% in pre-market trading. This sharp decline came despite the company reporting better-than-expected earnings for the third quarter of 2024 the previous day.</p>\n\n<p>While MannKind's Q3 2024 adjusted earnings per share of $0.05 surpassed analysts' estimates of $0.03, the company's revenue performance fell significantly short of expectations. MannKind reported revenue of $19.73 million, a staggering 61.5% lower than the year-ago quarter, missing analysts' projections of $74.50 million.</p>\n\n<p>The primary concern for investors appears to be the underwhelming performance of MannKind's flagship product, Afrezza, an inhaled insulin product for diabetic patients. Afrezza's net revenue grew by a modest 12% year-over-year in Q3 2024, primarily driven by higher demand and improved gross-to-net adjustments. However, the company acknowledged facing headwinds throughout the year, including payers implementing double step edits and a shift in inventory at a major pharmacy chain and one of its specialty pharmacies.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MannKind Shares Plunge Despite Q3 Beat as Afrezza Concerns Linger</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MannKind Shares Plunge Despite Q3 Beat as Afrezza Concerns Linger\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-08 22:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company focused on inhaled therapeutic products, took a nosedive on November 8, 2024, plummeting by 5.95% in pre-market trading. This sharp decline came despite the company reporting better-than-expected earnings for the third quarter of 2024 the previous day.</p>\n\n<p>While MannKind's Q3 2024 adjusted earnings per share of $0.05 surpassed analysts' estimates of $0.03, the company's revenue performance fell significantly short of expectations. MannKind reported revenue of $19.73 million, a staggering 61.5% lower than the year-ago quarter, missing analysts' projections of $74.50 million.</p>\n\n<p>The primary concern for investors appears to be the underwhelming performance of MannKind's flagship product, Afrezza, an inhaled insulin product for diabetic patients. Afrezza's net revenue grew by a modest 12% year-over-year in Q3 2024, primarily driven by higher demand and improved gross-to-net adjustments. However, the company acknowledged facing headwinds throughout the year, including payers implementing double step edits and a shift in inventory at a major pharmacy chain and one of its specialty pharmacies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凯德生物医疗","start_time":0,"source_url":"","article_id":"1177751945","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177751945","pubTimestamp":1731076626,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of MannKind Corporation , a biopharmaceutical company focused on inhaled therapeutic products, took a nosedive on November 8, 2024, plummeting by 5.95% in pre-market trading. This sharp decline came despite the company reporting better-than-expected earnings for the third quarter of 2024 the previous day.While MannKind's Q3 2024 adjusted earnings per share of $0.05 surpassed analysts' estimates of $0.03, the company's revenue performance fell significantly short of expectations. MannKind ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗"},"translate_title":"尽管第三季度表现出色，但由于Afrezza担忧挥之不去，MannKind股价仍暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1},"content_text":"Shares of MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company focused on inhaled therapeutic products, took a nosedive on November 8, 2024, plummeting by 5.95% in pre-market trading. This sharp decline came despite the company reporting better-than-expected earnings for the third quarter of 2024 the previous day.\nWhile MannKind's Q3 2024 adjusted earnings per share of $0.05 surpassed analysts' estimates of $0.03, the company's revenue performance fell significantly short of expectations. MannKind reported revenue of $19.73 million, a staggering 61.5% lower than the year-ago quarter, missing analysts' projections of $74.50 million.\nThe primary concern for investors appears to be the underwhelming performance of MannKind's flagship product, Afrezza, an inhaled insulin product for diabetic patients. Afrezza's net revenue grew by a modest 12% year-over-year in Q3 2024, primarily driven by higher demand and improved gross-to-net adjustments. However, the company acknowledged facing headwinds throughout the year, including payers implementing double step edits and a shift in inventory at a major pharmacy chain and one of its specialty pharmacies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}